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ABSTRACT   
The pathological diagnosis of adrenocortical carcinoma (ACC) relies on microscopic features 
that are sometimes equivocal in special variants, including oncocytic adrenocortical tumors 
(OACT). We report a series of 27 unpublished OACT (15 pure, 12 mixed or focal) and assess for 
the first time in OACT the diagnostic use of an algorithm recently proposed by our group 
("reticulin" algorithm) for conventional ACC, based on a combination of reticulin staining and 
assessment of only 3 Weiss parameters.  Overall, 12 cases were malignant according to the Lin-
Weiss-Bisceglia (L-W-B) system for pure and the original Weiss system for mixed or focal tumors; 
extensive or focal disruption of the reticulin network was found in 16/27 OACT, and was associated 
with either high mitotic index, presence of necrosis and/or vascular invasion in 14 of these, thus 
considered malignant according to our algorithm. From a clinical standpoint, OACT, at least in the  
pure forms are “low grade” lesions with low mean Weiss score, mitotic and Ki-67 indices, 
uncommon capsular or vascular invasion and generally pursue an indolent clinical course, even 
including unequivocal morphologically malignant cases. In addition, the 4977 bp mitochondrial 
DNA “common deletion” was detected using Real Time PCR in 54% of cases from the present and 
an additional validation series of 23 OACT, with a heterogeneous (heteroplasmic) intratissue and 
intracellular distribution, as detected by a modified FISH procedure, and a marked association with 
the presence of intact reticulin framework.   
 
KEY WORDS:  adrenal cancer, oncocytic variant, mitochondrial DNA, reticulin framework, 
classification. 
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INTRODUCTION 
Adrenocortical carcinoma (ACC) is an extremely rare (less than two cases per million individuals 
per year) and highly aggressive malignant tumor of the adrenal gland (6) (18) (25)(61) (62). A large 
fraction of cases presents with metastatic disease at diagnosis and the behavior is unpredictable, 
even in cases that underwent radical surgery (6) (25) (61). Progressing or advanced cases may 
benefit from chemotherapy (5), including new protocols based on mitotane (56), or by multi-agent 
therapy (6) (26) (40) (54). Disease relapse is however a major problem in many cases and to date, 
only radical surgery offers some prospect for better disease control (10) (48). Molecular studies 
have identified several genes, either related to control of tumor cell growth (cyclin D, IGF2, ß-
catenin) or to other cell functions which are differentially regulated in ACC compared to adenomas 
(ACA) or borderline tumors. Most of these may play a role in malignant progression, but so far 
none has proven sufficiently specific or sensitive for diagnostic purposes (2) (22) (24) (25) (39) (50) 
(51).  
Further, the correct classification of borderline adrenocortical tumors incompletely expressing the 
classical Weiss parameters is problematic and there is the concrete risk of over- or under-estimating 
the real biological potential of individual cases. In this respect, oncocytic adrenocortical tumors 
(OACT) represent the most challenging group, since some of the classical Weiss parameters, such 
as eosinophilic cytoplasm, nuclear atypia and diffuse growth are intrinsically present in the vast 
majority of these cases irrespective of their biological and clinical behavior. Therefore, the 
presently accepted cut-off value for malignancy, ie. Weiss score 3 (64) and subsequent 
modifications (3) may not be as accurate for OACT as in conventional ACC. In fact, at least a 
proportion of such cases would be overdiagnosed as carcinomas, since a Weiss score 3 is easily 
attained due to the innate morphology of OACT. 
This issue has been extensively discussed in the literature (35) and alternative classification systems 
have been proposed, of which the Lin-Weiss-Bisceglia system (L-W-B) is nowadays the most 
widely accepted (11) (34) (35) (45) (65). The L-W-B system is a modified Weiss scoring system for 
OACT (7) (8) (35) (65) based on major and minor criteria to more accurately classify these tumours 
as either benign, of borderline malignant, or frankly malignant potential. There are still some 
controversies in regard to this group of tumors. One is the existence of a borderline diagnostic 
category which – according to some (35) - largely reflects the scarcity of clinical information 
relating to the biologic behaviour. A second is the issue of any clear cell component in such tumors, 
specifically its pathobiological and clinical significance (7) (8). Further, OACTs are very 
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uncommon, with an unknown incidence worldwide and with only a total of 110 cases recorded so 
far (65). 
Recently, an algorithmic approach, the “reticulin” algorithm, was proposed for the diagnosis of 
conventional ACC (60), based on the combination of reticulin staining and three malignancy-related 
parameters (mitotic index, necrosis, vascular invasion), all of which had already been considered in 
the classical Weiss system, and none belonging to those intrinsically present in OACT, irrespective 
of their malignant potential. The performance of this algorithmic approach has never been tested 
specifically in OACT.  
Moreover, the molecular features of OACT, namely the presence of cytogenetic or mitochondrial 
DNA (mtDNA) alterations reported in oncocytic tumors of other locations (21) (23) (36) (37) (42)  
(44) (55) (59), have never been investigated in OACT.   
Therefore, the aims of this study were two-fold: i) to describe the clinicopathological features – 
including reticulin staining and the potential application of the newly proposed diagnostic algorithm 
- in an unpublished series of 27 adrenocortical tumors having more or less extensive oncocytic 
features; and ii) to determine the presence and tissue distribution of the most frequent mtDNA 
alteration, the 4977bp “common deletion”, examine its relationship to pathological and clinical 
parameters in individual tumors comprising these 27 cases, and to compare the findings to those in 
an external control series of OACT, most of which have been previously published (8) (65).  
We show that OACTs represent an heterogeneous group of tumors with morphological features 
resembling those of oncocytic neoplasms of other locations, including the presence of the mtDNA 
4977bp “common deletion”; and confirm OACT, in the pure form, as low grade tumors with a more 
indolent clinical course compared to conventional ACC. 
 
MATERIALS AND METHODS 
OACT Turin series (Table 1) – 194 consecutive adrenocortical tumors having a Weiss score >3 
(63) (64) collected between 1990 and 2010 from the pathology files of the University of Turin, were 
reviewed independently by three of us (ED, MV, MP) using a mean of five haematoxylin and eosin 
(H&E)-stained slides per case (range 1-22). This series included 35 cases resected at San Luigi 
Hospital, 24 cases originally collected by one of us (MP) at the San Giovanni Hospital of Turin 
from 1993 to 2003 and 135 cases received in consultation from different hospitals. The majority of 
these patients were treated at our Institution, which serves as a referral center for adrenocortical 
carcinoma in Italy. The histopathological features of 92 conventional ACC and 14 cases of the 
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myxoid variant belonging to this data set have already been reported (47) (60). Moreover, a series 
of 116 ACA, all resected at San Luigi Hospital between 1994 and 2008, with paraffin material and 
follow up information available was also reviewed. 
From this review, 27 cases were identified as OACT, of which, according to the criteria of Bisceglia 
et al (7), 15 were purely oncocytic (>90% oncocytes), while the remaining had a variable oncocytic 
component (30-80% oncocytes) combined with areas of conventional ACC or adenoma (10 were 
classified as mixed OACTs and 2 as focal OACT; Table 2). These 27 cases formed the basis of the 
current study. For all cases, the clinicopathological data (including information on treatment and 
outcome) were obtained and analysed. Six additional cases with oncocytic features accounting for 
<10% of the neoplasm were excluded. The study received ethical approval from the local Review 
Board of our Institution. 
 
OACT validation series (Table 3) and control cases – With the aim of verifying the prevalence of 
the mtDNA “common deletion” (see below), a separate validation series of 23 OACT classified 
using the L-W-B scoring system (8) retrieved from the files of the Casa Sollievo della Sofferenza 
Hospital of San Giovanni Rotondo (Italy) and PathWest Laboratory Medicine WA (Australia) was 
also investigated. This series included 16 pure oncocytic, 4 mixed, and 3 focal OACT cases. The 
clinicopathological features of some of these tumors (#16 – 15 pure and 1 mixed OACTs) had been 
previously reported [cases B6-B9 and B23 (7) (8), and W1-W3, W5, W10-W16 (65)] and thus were 
not further considered in this study. 
In addition, the mtDNA status was also investigated in a series of control cases including 18 normal 
adrenal glands obtained from nephrectomy specimens, 13 adrenocortical adenomas (none having 
oncocytic features with the exception of three showing <10% oncocytic changes) and 50 
conventional ACC. 
All the pathological material from the Turin, validation and control series was de-identified and 
coded by a pathology staff member not involved in the study prior to any type of analysis, to make 
all specimens anonymous to the investigators. 
 
Immunohistochemistry and histochemistry – Five µm thick paraffin sections serial to those used 
for conventional H&E staining were obtained for immunohistochemical and reticulin stains from 
one or two representative tissue blocks of all cases. The following antibodies were employed: melan 
A (DakoCytomation, Glostrup, Denmark; clone A103, diluted 1/50), alpha-inhibin (Diamedix, 
Miami, Florida; clone R1, diluted 1/75) and Ki-67 (Dako, clone MIB-1, diluted 1/150). A biotin-
free, dextran chain-based detection system (EnVysion, Dako) was used according to a standard 
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protocol and using diaminobenzidine as the chromogen. Reticulin histochemical staining was 
performed to define the status of the reticulin framework using a commercially available silver 
impregnation-based kit (Bio Optica, Milan, Italy). Disruption of the reticulin/basal membrane 
network was defined as the loss of continuity of the reticular fibre network evaluated at high 
magnification (400x) in more or less extensive tumor areas, as previously described (60). 
 
Mitochondrial DNA deletion screening by PCR – Molecular analysis was performed in all but 
five cases lacking informative material from the residual paraffin embedded tissue. Total DNA of 
OACT cases was obtained from macrodissected oncocytic areas by scraping five 10 µm-thick 
dewaxed sections into an Eppendorf tube using a sterile scalpel blade. A DNA extraction kit 
(QIAamp DNA Mini kit, Qiagen srl Italy, Milan, Italy) was used to isolate the DNA according to 
the manufacturer's recommendations. PCR primers used to detect a range of mtDNA deletions in 
the deletion-prone region (P1 and P2) and a mtDNA conserved sequence (P3 and P4) are listed in 
Table 4. PCR was performed using Maxima Hot Start Polymerase (Fermentas, Part of 
ThermoFisher Scientific, Waltham, MA, USA) and EvaGreen Dye, 20X in water (Biotium, 
Hayward, CA, USA) on the Rotor-Gene Q (Qiagen) apparatus. The cycling conditions were as 
follows: one cycle at 95°C for 5 minutes; 40 cycles at 95°C for 60 seconds, 56°C for 30 seconds, 
72°C for 90 seconds; 1 cycle at 72°C for 7 minutes; 5 cycles of fluorescence acquisition at 60°C; 
and one melt ramp from 65°C to 95°C. Whereas P3 and P4 primers generated the specific PCR 
product in all cases, samples with wild type mtDNA were not amplifiable using P1 and P2 primers 
that yielded the specific 380 bp PCR product only in the presence of the mtDNA common deletion. 
Mitochondrial DNA fluorescent in situ hybridization (FISH) analysis - FISH analysis was 
performed in all cases analyzed by means of PCR. To assess the mtDNA status, a two-color FISH 
procedure was performed as follows. Probes specific for both the deletion-prone and the rarely 
deleted regions of mtDNA were generated by means of PCR using a Long Template PCR System 
(Roche, Mannheim, Germany) according to the manufacturer's recommendations, using total DNA 
extracted from human umbilical cord fibroblasts. Primer sequences for FISH are listed in Table 4. 
The first probe („COM‟) bound to mtDNA at a rarely deleted region, and the second probe („DEL‟) 
bound in the vicinity of the deletion-prone region. PCR products were purified in Quantum Prep 
PCR Kleen Spin Columns (Bio-Rad Lab, Hercules, CA, USA) and 1 μg was labeled with 
digoxigenin (COM probe) or biotin (DEL probe) using a nick-translation labeling kit (Roche). The 
probes were tested prior to use on cultured human fibroblasts. FISH experiments were carried out 
on dewaxed 5 µm-thick sections according to Lewis et al. (36) and van de Corput et al. (58), with 
minor modifications. Slides were pretreated in a pressure cooker for five minutes at 125°C, 
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followed by a 10 second step at 90°C using citrate buffer (pH 6). They were then digested with 
0.1% (w/v) pepsin (Sigma, Steinheim, Germany) for 20 minutes at 37°C. RNAse A digestion (0.1 
mg/ml in PBS, Sigma) followed for one hour at 37°C, subsequently blocked in PBS. Finally, the 
sections were fixed in 1% formaldehyde in PBS for 20 minutes at room temperature, dehydrated in 
70%, 90% and 100% ethanols and air-dried. Both the digoxigenin-labeled COM and the 
biotinylated DEL probes were diluted in equal amount to a final concentration of 5 ng/µl in 
LSI/WCP Hybridization Buffer (Abbott Molecular, Des Plaines, IL, USA), then applied to sections 
and covered with a glass coverslip sealed with rubber cement. Negative control sections included 
omission of the probe from the hybridization mixture. Target DNA and probe were denatured 
simultaneously on an 80°C hot plate for five minutes and then incubated overnight at 37°C in a 
ThermoBrite System (Abbot Molecular, Des Plaines, IL, USA). Coverslips were carefully removed 
and slides were washed three times for five minutes each in 2X SSC and three times for 10 minutes 
each in TNT [100 mM Tris±HCl, 150 mM NaCl (pH 7.5), 0.05% Tween-20] at 45°C. Prior to probe 
detection, slides were incubated with a blocking solution (0.5% bovine serum albumin in 4X SSC) 
for 45 minutes at 37°C. The slides were then incubated simultaneously with anti-digoxigenin-
fluorescein Fab fragments (Roche, Mannheim, Germany) diluted 1/250, and with Streptavidin 
Alexa Fluor 594 (Molecular Probes, Invitrogen, Eugene, OR, USA) diluted 1/200 in blocking 
buffer, for 45 min at 37°C. Finally, sections were washed three times (10 minutes each) in TNT, 
dehydrated in 70%, 90% and 100% ethanols, air-dried and counterstained with DAPI (Abbott 
Molecular, Des Plaines, IL, USA). Sections were analysed using an Olympus BX61 fluorescence 
microscope and images were captured using the Cytovision 4.02 software package (Olympus Italia 
srl, Milan, Italy). Using this detection system, the green fluorescent probe (COM) bound all 
mtDNA molecules, whilst the red fluorescent probe (DEL) bound the deletion-prone region of 
mtDNA only in the absence of the deletion. Therefore, wild type mtDNA was defined by the 
presence of distinct yellow fluorescent dots or a ratio 1:1 of green and red dots, whereas the 
presence of an excess (at least 2:1 ratio) of green dots indicated the occurrence of the mtDNA 
deletion.  
 
Statistical analysis – Clinical and pathological variables were compared to mtDNA status and 
patient outcome by Fisher‟s exact or Chi-square and Student‟s t tests. A level of p<0.05 was 
considered statistically significant. All data were analyzed with STATISTICA for Windows 
software version 6.1 (StatSoft Italia, Vigonza, Padova, Italy).  
 
RESULTS 
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Clinicopathological data of OACT Turin series. 
The 27 OACTs affected 7 males and 20 females, with a median age of 48 years (range 28-68). The 
tumors were located in the right adrenal gland in 10 cases and in the left gland in 16, while in the 
remaining case the location was not reported. The hormonal status was known for all patients, of 
whom a functioning tumor was found in 13 (48%). Cortisol production was the most common event 
(eight patients), aldosteron production was observed in two cases, hypertension was present in two 
cases and androgen secretion in the remaining case (Table 1). Adjuvant mitotane treatment was 
administered in five patients who subsequently showed no disease progression, whilst first line 
chemotherapy (EDP protocol or mitotane alone) (6) was employed in four further cases at the time 
of disease progression.  
The tumors were generally large, with a mean diameter of 10 cm (range 1.6 to 23 cm). The mean 
weight of the 20 tumors for which this information was available was 141,5 gms (range 8–1300). 
The neoplastic oncocytes were similar in all cases, meeting their definition as cells with 
homogeneously deeply eosinophilic and granular cytoplasm. They had frequently atypical or bizarre 
nuclei with prominent nucleoli (Fuhrman grade 3 or 4), and eosinophilic nuclear pseudoinclusions 
were common. Since these Turin cases exhibited a more or less extensive population of oncocytes, 
two subgroups could be identified.  
Pure OACT (15 cases). This main subgroup included OACTs (cases #1 to 15) in which oncocytes 
accounted for more than 90% of the tumor area (Figure 1). The tumor cells were arranged 
predominantly or entirely in a diffuse, “patternless pattern”, with trabecular, alveolar, and 
microcystic areas occasionally observed as a minor component. A variable cell size was observed, 
with 4/15 cases (cases 8, 9, 12, 13) being composed predominantly of small oncocytes. These cells 
had a deeply eosinophilic cytoplasm, but a reduced volume and small, centrally located, mildly 
atypical nuclei. Bizarre multinucleated giant cells, patchy mononuclear inflammatory cell infiltrates 
and fibromyxoid stroma were occasionally observed. One tumor was associated with a  
myelolipomatous component. Additional pathological parameters included necrosis in seven, 
whereas mitotic index was <5/50HPF in 14 cases and only in one case (# 15) there was a relatively 
high mitotic count (15/50 HPF) with atypical mitotic figures. Invasion of vessels and/or capsule was 
a feature of five and three cases, respectively. As a result, based on the proposed L-W-B system for 
OACT (which excludes the so-called “definitional criteria” of the classical Weiss parameters), a 
diagnosis of malignancy was confirmed in six tumors only. These all manifested  1 of the “major 
criteria” of the L-W-B system (mitotic rate > 5/50HPF, atypical mitoses and venous invasion). The 
remaining cases were classified eight as OACT of UMP, since one or more “minor criteria” 
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(necrosis, capsular invasion, sinusoidal invasion, diameter >10 cm and/or weight >200 gms) only 
were identified, and one benign case. Five of the UMP cases defined by L-W-B were benign using 
the “reticulin” algorithm (see below).  
Mixed and Focal OACT (12 cases). This second subgroup included 12 cases (#16 to 27), in which 
oncocytes constituted 30-80% of the tumor area. The cytoarchitectural features of the oncocytic 
component were comparable to the pure OACT. The oncocytic cell population was either separate 
from, or intermingled with the non-oncocytic component (Figure 1e). At variance with pure OACT 
cases, a prevalence of medium-small sized oncocytes was observed. The non-oncocytic cell 
population was composed of pleomorphic atypical cells having a diffuse growth pattern, as seen in 
conventional ACC. Since the L-W-B system was originally devised for pure OACT only and could 
not be applied to this mixed/focal oncocytic tumor subgroup, we applied the classical Weiss scoring 
system here, that recognized six benign and six malignant cases. Using the “reticulin” algorithm, 7 
cases were scored benign and the  remaining  5  were qualified as malignant (see below). 
 
Immunohistochemical and histochemical features  
Immunoprofile and Tumor Proliferation Fraction - All tumors in this series shared the expression 
of at least one of the more reliable markers of the adrenal cortex, namely melan A and alpha-
inhibin. The mean Ki-67 proliferation index was 5.6% in the subgroup of pure OACT (range 1% - 
20%), with mean values of 1% for the benign case, 2% for borderline tumors and 6.5% for 
malignant ones, while among mixed/focal OACTs it was 6.8% (range 1-40%), being 1.3% for 
benign and 12.3% for malignant cases. 
 
Evaluation of reticulin framework and application of the “reticulin” diagnostic algorithm - As 
recently reported by our group (60), a histochemical stain for reticulin was performed in each case. 
This demonstrated disruption of the stromal framework in 16/27 (11/15 pure and 5/12 mixed) 
OACT cases of the Turin series, and in 19/23 (15/16 pure and 4/7 mixed and focal) cases of the 
validation cohort (Table 1 and 3). The reticulin disruption was either focal (13 cases) or extensive. 
In mixed/focal OACT, disruption of the reticulin network was more evident in conventional (non-
oncocytic) carcinoma components, whereas an intact reticulin framework, if present, was mostly 
recognized in the oncocytic component (Figure 1). 
An intact reticulin framework in the present series was observed in 11 cases (4 pure OACT, 7 
mixed OACT), all composed of large sized oncocytes. Three out of four pure OACT with intact 
reticulin framework were classified as being of UMP by L-W-B criteria but as benign according to 
the “reticulin” algorithm. In addition, one mixed OACT was classified as malignant by the classical 
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Weiss scoring system and benign by the “reticulin” algorithm. Thus, all cases with intact reticulin 
were benign by the “reticulin” algorithm, and indeed, this finding was associated to a non-malignant 
condition in our cases. However, it should be noted that in this series of OACT, apparently at 
variance with conventional ACC, some malignant cases had only focal reticulin disruption that 
might be under-estimated or missed in single sections. Using the reticulin stain as an inclusion 
criterion of the “reticulin” algorithm in the Turin series only, 13 cases (6 pure and 7 mixed OACT) 
were categorized as benign and 14 as malignant (disrupted reticulin framework together with at 
least one of the following criteria: necrosis, high mitotic rate and vascular invasion). Two cases 
with reticulin disruption but lacking any of the additional criteria for malignancy were classified as 
benign (Table 1).  
 
 
Mitochondrial DNA alterations   
Prevalence of mtDNA “common deletion” as detected by PCR. The presence of the mtDNA 
“common deletion” was successfully analysed by means of real-time PCR in OACT cases having  
informative tissue available. In the Turin series, it was present in 12/22 cases (54%), including 6/13 
pure and 6/9 mixed cases (Figure 2). A similar positive proportion was observed in the validation 
cohort: 8/23 cases (35%), including 5/16 pure and 3/7 mixed (2) or focal (1) tumors. Overall in the 
two series, according to the L-W-B classification for pure OACT or the Weiss system for the mixed 
and focal OACT, the mtDNA deletion was found in 15 benign or UMP cases and only 5 malignant 
OACT. When compared to the reticulin staining, 12/14 cases (86%) with intact reticulin framework 
had the mtDNA common deletion, whereas a lower proportion of the reticulin-disrupted cases 
harboured the deletion (8/31, 26%); the difference was statistically significance (Fisher‟s test 
p=0.0003). In control cases of non-oncocytic adrenal tissues/tumors, the mtDNA common deletion 
was detected in 4/18 normal adrenal, 5/13 adrenocortical adenomas, but in none of 50 conventional 
ACC.  
Tissue patterns and distribution of mtDNA “common deletion” by means of FISH. FISH analysis 
was performed in all PCR-tested cases, and the results were reliable in all but seven cases (mostly 
due to poor tissue preservation). There was 100% concordance between an altered FISH pattern and 
the PCR detection of the mtDNA common deletion (Figure 2). The tissue and cellular distribution 
of such mtDNA alterations were not present uniformly in all tumor cells in any individual case. 
Rather, the alteration was limited to only a fraction of neoplastic cells in the majority of cases 
(intratissue heteroplasmy), nor was it present in all mitochondria of deletion-bearing oncocytes 
(intracellular heteroplasmy). Interestingly, the presence of intracellular heteroplasmy was more 
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commonly associated with a diagnosis of “malignancy”, whereas all 11 cases with intracellular 
homoplasmy were classified as benign or UMP, according to the L-W-B criteria.  
 
Correlation of OACT classification and mtDNA alterations with clinical outcome 
Follow-up data were available for all 27 cases in the Turin series. Although the number of cases is 
too small for survival analysis, the disease status was compared using the alternate classification 
systems (to test their ability to identify cases following a clinically malignant behavior), as well as 
with reticulin staining alone and with the presence of the mtDNA “common deletion”. Two 
clinically aggressive cases were classified as being of UMP, rather than malignant, using the L-W-B 
proposal for OACT classification. When the reticulin stain alone or the “reticulin” algorithm were 
applied, a specificity of 57% and 62% were observed, respectively, but both methods were 100% 
sensitive in identifying cases with recurrence or disease-related deaths. A statistical correlation 
between the reticulin algorithm  and the L-W-B system could not be performed due to possible 
selection bias and small sample size. However the “reticulin” algorithm, which was initially 
proposed for conventional ACC (60), appeared to be diagnostically applicable also in the oncocytic 
group of adrenocortical lesions. By contrast, the presence of the mtDNA “common deletion” was 
not invariably associated with a more favourable clinical outcome, also having been detected in a 
single patient who died of disease 20 months after diagnosis. 
 
DISCUSSION  
 
In the present paper, we reviewed the pathological features of an unpublished series of 27 
adrenocortical tumors the large majority having more or less extensive oncocytic features, and 
confirmed the diagnostic value of reticulin staining and of a diagnostic algorithm recently proposed 
by our group (60) in distinguishing clinically malignant from benign OACT. In addition, we traced 
the mitochondrial DNA deletion commonly described in oncocytic tumors of other organs in a 
proportion of OACT, mostly in cases with an intact reticulin framework, although rare clinically 
aggressive cases also bore the deletion.  
Diagnostic features of OACT. A large series of 194 ACC and 116 ACA was reviewed to search for 
oncocytic features, and 27 cases (approximately 10% of the whole series) met the classic 
morphological criteria for the diagnosis of oncocytic tumors of other organs (4) (12), and adrenal 
gland, in particular (7) (8) (35) (65).  
These include a tumor cell population of large cells with eosinophilic and granular cytoplasm, 
generally showing a diffuse growth pattern and high grade nuclear atypia (7) (8) (35) (65). By 
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definition (pure) OACT were composed (almost) exclusively (>90%) of oncocytic cells; however a 
minor proportion of cases (12 of 20 in the Turin series and 7 of 23 in the validation group) showed a 
variable component of (non-oncocytic) adrenocortical clear tumor cells (mixed OACT and focal 
OACT). Interestingly, a number of cases, all pure OACT, were composed of predominantly small 
cells, an occurrence which had been already observed (8) (65), and that, in contrast to the findings 
reported in poorly differentiated oncocytic carcinomas of the thyroid gland (46), did not predict for 
a different behavior in the OACT. Further unusual findings were: i. the presence of stromal myxoid 
foci, which were seen in a single case of the Turin series though not to the extent to allow their 
classification as the OACT counterpart of the myxoid variant of conventional ACC (47);  ii. the 
presence of a myelolipomatous component in a case of pure OACT. Both fibromyxoid stromal foci 
and a lipomatous component in pure OACT were also described in the validation series (65).  
The definition of malignancy in OACT is problematic if the classical Weiss criteria are applied 
for classification, as first suspected by Lin et al (38). In fact, 20/27 cases from the Turin series, 
having significant numbers of cells with eosinophilic cytoplasm, nuclear atypia and diffuse growth 
(“definitional criteria” (7) (8)), achieved the minimal Weiss score 3 for a diagnosis of malignancy, 
thus suggesting a risk of overestimating potential malignancy in the OACT tumor group if the 
Weiss scoring system is employed as a diagnostic tool. Therefore, following our recent proposal of 
a newly designed algorithm for the diagnosis of conventional ACC (60), we tested its diagnostic 
usefulness in the group of OACT. The recognition of the presence of a disrupted reticulin network 
together with the presence of any of 3 clear-cut morphological signs of malignancy (high mitotic 
index, necrosis and vascular invasion) was able to segregate clinically benign from malignant cases 
with optimal performance, with no cases in the “benign” group following an aggressive course 
included, provided that an accurate search for even focal reticulin disruption was performed. 
Indeed, while in conventional adrenocortical tumors, all malignant (i.e. Weiss score > 3) cases had 
disrupted reticulin framework (60), in OACT the reticulin pattern was more heterogeneous, possibly 
due to the association with (residual?) low grade “oncocytoma” areas in a fraction of cases. 
Reticulin distribution pattern or loss in OACT (both pure, mixed, and focal) likely deserves the 
same attention pathologists devote when they examine difficult or equivocal tumoral hepatocellular 
lesions. Thus a careful search for even focal reticulin disruption is necessary in more than one 
paraffin block, before reliably excluding any reticulin alteration. Notably, in the mixed and focal 
OACT, reticulin disruption was more evident in conventional ACC areas, whereas in some cases 
the oncocytic component showed a preserved reticulin framework. In any case, this simplified 
algorithmic approach has the advantage of reducing the evaluation of multiple Weiss parameters, 
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which in OACT are either not applicable (“definitional criteria” according to the L-W-B scheme), 
or may be of equivocal and/or subjective definition (such as sinusoidal and capsular invasion). 
 Apart from these practical diagnostic considerations, it should be stressed that pure OACT are “low 
grade” lesions, with a low mean Weiss score, frequent preservation of the reticulin network, low 
mitotic and Ki67 proliferation indices, and uncommon capsular or vascular invasion. Even 
considering unequivocally morphologically malignant cases only, most tumors followed an indolent 
clinical course. Although a direct comparison with conventional ACC was not possible due to the 
limited number of OACT cases, a better outcome was observed, with only three of 14 pure OACT 
in our series developing recurrence or metastases (though in 2 cases follow-up is still short, <24 
months). These outcomes approximate those of  “oncocytomas” of some other organs (kidney and 
salivary gland) which generally follow an indolent course and are in any case associated with a 
lower grade than their conventional carcinoma counterparts. These data are in accordance with the 
previous study of Wong et al (65) who provided the first preliminary statistical evidence of an 
improved prognosis of malignant OACT as compared to conventional ACC (overall median 
survival of 58 months versus 14-32 months).  
By contrast, whether mixed and focal OACT share the same favorable behaviour remains to be 
proven, though we strongly suspect this will not be the case.  In our very limited data set of 5 
malignant cases with follow-up (all from Turin; range 16-165 months) 3 patients died of disease 
within  20-97 months, two of whom died in less than 24 months. 
Prevalence of mitochondrial DNA “common deletion” in OACT. The identification of 
pathological and clinical similarities with oncocytic tumors of other organs led us to question 
whether OACT may also display molecular abnormalities in the mitochondrial DNA. We focused 
on the analysis of the presence of the mtDNA 4977 bp “common deletion” by means of two 
alternative methods, a PCR based technique and a FISH procedure to establish the cell and tissue 
localization of the molecular changes. The “common deletion” is the most common somatic 
mtDNA abnormality detected in oncocytic tumors of various organs (37) (42) (59). It occurs 
between two 13-bp direct repeats (at positions 13447–13459 and 8470–8482) of the human 
mtDNA. This portion of mtDNA encompasses five tRNA genes and seven genes encoding subunits 
of cytochrome c oxidase, complex I and ATPases (53). By means of PCR, the mtDNA “common 
deletion” was detected in approximately 50% of cases, both in the Turin cases and in the external 
validation cases. Interestingly, such mtDNA alteration was slightly more prevalent in pure OACT 
and in cases classified as benign or of UMP, according to both the L-W-B classification and the 
“reticulin” algorithm, but, although these findings are of potential pathogenetic interest, to date the 
analysis of the presence of the mtDNA “common deletion” has no practical diagnostic value. 
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Further, to answer the question whether the “common deletion” of mtDNA was a feature of all cells 
of individual oncocytic tumors (as a result of a “clonal” event) or an heterogeneous event, FISH 
analysis was performed with probes specific for the preserved (green) and the deleted regions (red), 
as previously described in the Warthin tumor model of salivary glands (36). The concordance 
between PCR and FISH methods was 100%. There was a relatively high degree of intercellular and 
intracellular heteroplasmy, with the deletion being detected in some, but not other tumor areas, and 
heterogeneously within single tumor cells in most cases. This observation probably indicates that 
this feature is not clonally transmitted to all neoplastic cells and probably represents an early change 
in the mtDNA which is maintained in a subpopulation of oncocytes only, and likely has no role in 
malignant progression. Rather, it could act as a tumor suppression mutation (17). In support of this 
hypothesis, the same mtDNA alteration was detected at a comparable rate in control cases of normal 
adrenal cortex and adrenocortical adenoma, but not in conventional ACC. It should be noted that 
such mtDNA deletion is not specific for oncocytic tumors, but has also been reported in normal 
tissues and in several pathological conditions not specifically associated with an oncocytic 
phenotype, including non-neoplastic (9) (14) (15) (19) (27) (28) (30) (31) (41) (49) (66)  and 
neoplastic conditions (13) (1) (16)(20) (29) (32) (33)  (43) (52) (57).  
In conclusion, a) OACT represent an heterogeneous group of tumors with morphological features 
resembling those of oncocytic neoplasms of other locations; b) the “reticulin” diagnostic algorithm 
seems to well recognize clinically aggressive cases and to overcome the risk of under-estimating 
malignancy in this tumor group; c) malignant OACT, especially in their pure form, are low grade 
tumors with a more indolent clinical course as compared to conventional ACC; d) the mitochondrial 
DNA “common deletion” described in other oncocytic human tumors is also present in a fraction of 
OACT (approximately 50%); e) such mtDNA alteration is also present in normal adrenal cortex and 
in adrenocortical adenomas, but has never been identified in conventional ACC.  
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LEGENDS FOR FIGURES 
FIGURE 1. Oncocytic adrenocortical tumors (OACT). (A, B, case #4) Pure form with 
homogeneous growth of large atypical cells. In a serial section (B), the reticulin framework appears 
entirely preserved. The tumor has a low proliferative index (1%, inset). This case was scored as 
UMP according to Lin-Weiss-Bisceglia (L-W-B) classification. A malignant OACT according to L-
W-B is shown in C and D (case #13), where a diffuse growth of medium/small sized oncocytes (C) 
is associated with a reticulin network disruption (D). The proliferative index was 10% (C, inset). In 
mixed OACT (E, F, case #22) two cell populations coexist, with oncocytic cells (E, bottom left) 
having a very low proliferative index (E, inset bottom left) adjacent to conventional carcinoma 
areas (E, top right) with a proliferative index up to 40% (E inset, top right). These two components 
have a different reticulin framework pattern, appearing intact in oncocytic areas (F, bottom left) and 
disrupted in conventional carcinomas ones (F, top right). In pure OACTs, either classical, large, 
granular oncocytes (G case #4) or small, mildly atypical oncocytes (H, case #13) can be observed. 
[Hematoxylin & Eosin, original magnification 200x in A, C, E; 400x in G, H. Insets: 
immunoperoxidase for Ki67; original magnification 400x in A, C; 200x in E. Histochemical 
reticulin stain, original magnification 200x in B, D, F]. 
 
FIGURE 2. Assessment of the mitochondrial DNA (mtDNA) 4977 bp “common deletion” in 
oncocytic adrenocortical tumors. In A and B a non deleted case is shown (case #10), while in C and 
D, an example of mtDNA deletion is represented (case #4). By PCR, P3 and P4 primers against a 
mtDNA conserved region generated the specific PCR product (green curve) in both cases (A, C) 
while P1 and P2 primers yielded the specific 380 bp PCR product (red curve) only in the presence 
of the mtDNA “common deletion” (C) [see also Materials and Methods]. By FISH analysis, the 
green fluorescent probe (COM) bound all mtDNA molecules, whilst the red fluorescent probe 
(DEL) bound the deletion-prone region of mtDNA only in the absence of the deletion. A prevalence 
of distinct yellow fluorescent dots corresponding to a 1:1 ratio of green and red dots (B) confirmed 
the presence of normal mtDNA, whereas the excess (at least 2:1 ratio) of green dots (D) confirmed 
the occurrence of the 4977 bp “common deletion”.  
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Table 1. Clinico-pathologic and mitochondrial DNA alterations  in 27  OACT. 
 
 
Sex/ 
Age 
Hormone 
production 
Location/ 
Weight (gr) 
Size (cm) 
Oncocytic 
area (%) 
Classification 
System 
Reticulin 
stain 
Reticulin 
Algorithm 
PCR 
mtDNA 
deletion 
FISH 
mtDNA 
pattern 
Follow  
up 
(mos) 
Pure OACT 
   
 LWB 
classification 
 
   
 
1 F/45 contisol L/9/3 >90 benign intact ACA YES deleted NED 36 
2 F/47 not funct R/30/ 3 >90 UMP intact ACA  NO normal NED 72 
3 F/45 not funct R/ NA/ 5.5 >90 UMP intact ACA YES deleted NED 24 
4 F/45 not funct R/NA/ 4 >90 UMP intact ACA YES deleted NED 36 
5 F/61 androgens L/1252/ 17 >90  UMP disrupted ACA YES deleted alive 60 
6 F/49 not funct L/400/13 >90 UMP disrupted§ ACA NO normal alive 124 
7 F/61 not funct L/400/12 >90 UMP disrupted§ ACC (necrosis) YES deleted NED 165 
8 F/41 not funct L/NA/ 11   >90 ^ UMP disrupted ACC (necrosis) NO normal AWD 72 
9 F/42 not funct L/530/16   >90 ^ UMP disrupted ACC (necrosis) NO na DOD 15 
10 F/31 hypertens. L/255/ 9.5 >90 malignant disrupted§ ACC (venous invasion) NO normal alive 113 
11 M/60 not funct L/8/ 1.6 >90 malignant disrupted§ ACC (mitoses) NO normal NED 48 
12 F/68 not funct R/NA/ 17   >90 ^ malignant disrupted§ ACC (necrosis, venous invasion) NO normal NED 36 
13 F/66 not funct NA   >90 ^ malignant disrupted ACC (necrosis, venous invasion) YES deleted NED 11 
14 M/46 not funct L/950/18 >90 malignant disrupted ACC (necrosis, venous invasion) nd nd NED 4 
15 M/32 not funct R/NA/ 23 >90 malignant disrupted ACC (necrosis, mitoses , venous invasion)  nd nd DOD 24 
Mixed / Focal 
OACT 
   
 Classical 
WSS 
     
16 F/53 hypertens L/135/8 60 benign intact ACA YES deleted NED 108 
17 F/66 aldosteron R/52/5 60 benign intact ACA YES deleted NED 72 
18 M/50 cortisol L/18/4 50 benign intact ACA YES deleted NED 92 
19 F/55 cortisol R/86/11 50 benign intact ACA NO normal NED 55 
20 F/37 cortisol L/7.3/2.8 50 benign intact ACA YES deleted NED 47 
21 F/40 aldosteron R/10/4 30 benign intact ACA YES deleted NED 43 
22 F/44 cortisol R/NA/ 8 60 malignant disrupted ACC (necrosis) NO normal DOD 90 
23 M/35 not funct L/40/8 50 malignant intact ACA nd nd NED 60 
24 F/67 cortisol L/1050/15 60 malignant disrupted ACC (necrosis, venous invasion) NO normal NED 156 
25 M/44 cortisol R/1300/20 40 malignant disrupted ACC (necrosis, venous invasion) YES deleted DOD 20 
26 F/46 not funct L/270/ 9.9 70 malignant disrupted  ACC (necrosis, mitoses , venous invasion) nd nd NED 64 
27 M/28 cortisol L/210/11 80 malignant disrupted ACC (necrosis, mitoses , venous invasion) nd nd DOD 23 
 
Abbreviations: M: male, F: female; not funct: non functioning; hypertens: hypertension; L: left; R: right; NA: not available; LWB: classification for 
pure OACT according to Lin-Weiss-Bisceglia; WSS:Weiss scoring system. UMP: uncertain malignant potential; ACC: adrenocortical carcinoma; 
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ACA: adrenocortical adenoma; mtDNA: mitochondrial DNA; nd: not done; na: not adequate; mos: months; NED: no evidence of disease; AWD: alive 
with disease; DOD: died of disease.  ^: small size oncocytes predominant; §: focal reticulin disruption 
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Table 2. Selection criteria of currently investigated OACT, according to the proposed classification system (7) (8) (65) 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ACT: Adrenocortical tumor; OACT: Oncocytic adrenocortical tumor 
*: excluded from the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Composition 
 
Pure OACT 
(%) 
Mixed 
OACT 
(%) 
Focal 
OACT 
(%) 
(Pure) 
Conventional 
ACT (%)* 
Oncocytic > 90 50 - 90 
 
10 - <50 < 10 
Clear cell 
 
< 10 10 - < 50  50 - 90 > 90 
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Table 3. Validation cohort of 23 OACT investigated for reticulin status and mitochondrial DNA alterations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: LWB: classification for pure OACT according to Lin-Weiss-Bisceglia; UMP: uncertain malignant potential; mtDNA: mitochondrial 
DNA; na: not adequate; WSS: Weiss scoring system. 
*: In these cases, tissue from recurrence (B7, W10, W16) and metastasis (W15) was also tested with similar results as in the primary tumor, except 
for mtDNA detection of case W15 which was restricted to the primary;       
§: focal reticulin disruption. 
 
 
Classification 
System 
Oncocytic 
area (%) 
Reticulin stain 
PCR mtDNA 
deletion 
FISH 
mtDNA 
pattern 
Pure OACT LWB classification     
W1 benign  >90 disrupted NO na 
W2 benign  >90 disrupted § YES deleted 
W3 UMP >90 intact YES na 
W4 UMP  >90 disrupted § NO na 
W5 UMP  >90 disrupted § YES deleted 
B6 UMP  >90 disrupted NO normal 
B7  malignant >90 disrupted* NO* na 
B8 malignant >90 disrupted NO normal 
B9 malignant >90 disrupted § NO na 
W10  malignant  >90 disrupted* NO* normal 
W11 malignant  >90 disrupted YES deleted 
W12 malignant  >90 disrupted NO normal 
W13 malignant  >90 disrupted NO normal 
W14 malignant  >90 disrupted NO normal 
W15  malignant  >90 disrupted* YES* deleted 
W16  malignant  >90 disrupted §* NO* normal 
Mixed / Focal 
OACT 
Classical WSS      
W17 benign 60 intact YES deleted 
W18 benign 10 intact YES deleted 
W19 malignant 60 intact YES deleted 
W20 malignant 60 disrupted § NO normal 
 W21 malignant 70 disrupted NO normal 
W22 malignant 40 disrupted NO na 
B23 malignant 75 disrupted NO normal 
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Table 4. PCR primers [mtDNA accession number NC-012920] 
_________________________________________________________________________ 
Detection of mtDNA common deletion by means of PCR  
P1  nucleotides  8286-8305 5‟-TCTAGAGCCCACTGTAAAG-3‟  
P2 nucleotides  13662-13643  5‟- GTTAGTAAGGGTGGGGAAGC-3‟ 
P3 nucleotides  4504-4526 5‟- CCATCTTTGCAGGCACACTCATC-3‟ 
P4 nucleotides  4955-4977 5‟- ATCCACCTCAACTGCCTGCTATG-3‟ 
 
Primers for the generation of FISH probes 
COM  probe   forward   nucleotides  13972-13949  5‟-CCTATCTAGGCCTTCTTACGAGCC-3‟ 
COM  probe   reverse  nucleotides   4468-4440 5‟-AGTACGGGAAGGGTATAACCAACATTTTC-3‟  
DEL  probe   forward  nucleotides    8848-8873 5‟-TTATGAGCGGGCACAGTGATTATAGG-3‟  
DEL  probe   reverse  nucleotides    12864-12839 5‟-ACGGTTGTATAGGATTGCTTGAATGG-3‟ 
________________________________________________________________________________ 
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